JP2017519008A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519008A5
JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
Authority
JP
Japan
Prior art keywords
serelaxin
pharmaceutical formulation
patient
biological sample
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519008A (ja
JP6820748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054399 external-priority patent/WO2015189790A1/en
Publication of JP2017519008A publication Critical patent/JP2017519008A/ja
Publication of JP2017519008A5 publication Critical patent/JP2017519008A5/ja
Application granted granted Critical
Publication of JP6820748B2 publication Critical patent/JP6820748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572697A 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用 Expired - Fee Related JP6820748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (3)

Publication Number Publication Date
JP2017519008A JP2017519008A (ja) 2017-07-13
JP2017519008A5 true JP2017519008A5 (https=) 2018-07-19
JP6820748B2 JP6820748B2 (ja) 2021-01-27

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572697A Expired - Fee Related JP6820748B2 (ja) 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用

Country Status (11)

Country Link
US (2) US20170100460A1 (https=)
EP (1) EP3154559B1 (https=)
JP (1) JP6820748B2 (https=)
KR (1) KR20170018829A (https=)
CN (1) CN106413740A (https=)
AU (2) AU2015273097A1 (https=)
BR (1) BR112016028833A2 (https=)
CA (1) CA2952061A1 (https=)
MX (1) MX2016016414A (https=)
RU (1) RU2016147122A (https=)
WO (1) WO2015189790A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015077540A2 (en) 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
CN114025675A (zh) * 2019-06-20 2022-02-08 索尼集团公司 信息处理装置、信息处理方法和程序

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE511656T1 (de) * 2006-08-04 2011-06-15 Hannover Med Hochschule Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
CN102036679A (zh) * 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2017519008A5 (https=)
Guo et al. Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation
Ingenbleek et al. Plasma transthyretin as a biomarker of lean body mass and catabolic states
Mondal et al. Stress hyperglycemia ratio, rather than admission blood glucose, predicts in-hospital mortality and adverse outcomes in moderate-to severe COVID-19 patients, irrespective of pre-existing glycemic status
Yanishi et al. Factors associated with the development of sarcopenia in kidney transplant recipients
Grodin et al. Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF
Behr The diagnosis and treatment of idiopathic pulmonary fibrosis
Peck-Radosavljevic et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)
Karavanaki et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
JP2016520573A5 (https=)
Zhang et al. The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism
Lin et al. Preliminary prospective study to assess the effect of early blood urea nitrogen/creatinine ratio-based hydration therapy on poststroke infection rate and length of stay in acute ischemic stroke
Lazzeri et al. Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization
Nazim et al. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes
de Almeida Faro et al. Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia
Sato et al. Therapeutic targets and early stage clinical trials for pulmonary fibrosis
Gores et al. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy
Sharma et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea
Csobay-Novák et al. Decreased plasma nociceptin/orphanin FQ levels after acute coronary syndromes
Rouini et al. Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage
Kaman et al. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support
Yamaguchi et al. A case of severe hypothyroidism causing cardiac tamponade associated with lithium intoxication
Shinohara et al. Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance